Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration

Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration

Abstract Background Current clinical guidelines recommend epidermal growth factor receptor (EGFR) mutational testing in patients with metastatic non-small cell lung cancer (NSCLC) to predict the benefit of the tyrosine kinase inhibitor erlotinib as first-line treatment. Proteomic (VeriStrat) testing...

Full description

Bibliographic Details
Main Authors: Olga Efimova, Brygida Berse, Daniel W. Denhalter, Scott L. DuVall, Kelly K. Filipski, Michael Icardi, Michael J. Kelley, Julie A. Lynch
Format: Article
Language:English
Published: BMC 2017-05-01
Series:BMC Medical Informatics and Decision Making
Subjects:
Biomarker
Proteomic
Genomic
Testing algorithm
Non-small cell lung cancer
VeriStrat
Online Access:http://link.springer.com/article/10.1186/s12911-017-0475-8

Internet

http://link.springer.com/article/10.1186/s12911-017-0475-8

Similar Items